# Jack Geremia

> Jack Geremia is the CEO and co-founder of Matterworks, a Somerville, Massachusetts biotech building Large Spectral Models - foundation models that read raw mass spectrometry signals the way a large language model reads text. A Princeton-trained chemist and former Caltech quantum-control postdoc turned serial biotech founder, he has spent 25-plus years moving technologies from lab bench to market, authoring more than 100 patents and publications. After co-founding Matterworks in 2019 as advising CTO, he stepped into the CEO seat to commercialize Pyxis, the company's generative-AI engine for untargeted molecular annotation, and led the company through a 2025 Series A from Lewis & Clark Partners and OMX Ventures.

- **Role:** CEO & Co-Founder at Matterworks
- **Organizations:** Matterworks, Kaleido Biosciences, Midori USA, Inc., DSM Nutritional Products, Midori Animal Health
- **Nationality:** American
- **Education:** Ph.D. in Chemistry, Princeton University, Honors B.S. in Chemistry & Biochemistry, University of Delaware, B.S. in Biochemistry, University of California, Davis, Postdoctoral Fellowship, Control & Dynamical Systems (Division of Engineering & Applied Science), California Institute of Technology (Caltech)
- **Known for:** Co-founded Matterworks (2019) and was named its CEO, Author of more than 100 patents, patent applications, and scientific publications, Led Matterworks' Series A funding round (June 2025)

## Career timeline

- **2001-2005** — Postdoctoral fellow in Control & Dynamical Systems at Caltech
- **earlier** — Founder & CSO of Midori Animal Health, later acquired by DSM
- **post-acquisition** — Global Head of Microbiome Discovery at DSM Nutritional Products
- **later** — Founder & Head of Technology at Midori USA, Inc.
- **later** — Vice-President of R&D at Kaleido Biosciences
- **2019** — Co-founded Matterworks with Mimoun Cadosch Delmar; served as advising CTO
- **2024** — Matterworks launched Pyxis, generative AI for untargeted molecular annotation from mass spec
- **2024** — Delivered main-stage lightning talk at SynBioBeta 2024: 'When will phenotype prediction be reality?'
- **2025** — Named CEO of Matterworks; led 2025-06-03 Series A from Lewis & Clark Partners and OMX Ventures

## Achievements

- Co-founded Matterworks (2019) and was named its CEO
- Author of more than 100 patents, patent applications, and scientific publications
- Led Matterworks' Series A funding round (June 2025)
- Pioneered the Large Spectral Model (LSM) concept for molecular-omic data
- Oversaw the launch of Pyxis, described as the first generative AI for complete untargeted molecular annotation from mass spectrometry
- Built and exited multiple early-stage biotech companies across animal, human, and agricultural health

## Latest updates

- **2025-06** — Matterworks closed its Series A (announced June 3, 2025) led by Lewis & Clark Partners and OMX Ventures to scale its model-as-a-service business.
- **2025-06** — Named CEO of Matterworks, with Carolyn Fritz joining the board.

## Links

- Website: https://matterworks.ai
- LinkedIn: http://www.linkedin.com/in/jmgeremia

---

Profile page: https://yespress.io/jack-geremia
Published by YesPress — https://yespress.io
Last updated: 2026-06-12